Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 173, Issue 11, Pages 1101-1109Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2016.15081101
Keywords
-
Categories
Funding
- NIMH [U01MH055495, U01MH081362, U01MH086127, U01MH086130, U01MH08612005, U01MH084241, U01MH086122]
- Alkermes
- Assurex
- Avanir
- Cyberonics
- Brainsway
- MagStim
- NARSAD
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- NeoSync
- Neuronetics
- NIDA
- NIMH
- Stanley Foundation
- St. Jude Medical (Advanced Neuromodulation Systems)
- American Foundation for the Prevention of Suicide and NIMH
- Amgen
- AstraZeneca
- Corcept
- Eli Lilly
- Proteus
- St. Jude Medical
- Sunovion
- Brain and Behavior Research Foundation
- Stanley Medical Research Foundation
- Nexstim
- NIH
Ask authors/readers for more resources
Objective: The Prolonging Remission in Depressed Elderly (PRIDE) study evaluated the efficacy of right unilateral ultra brief pulse electroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geriatric depression. Method: PRIDE was a two-phase multisite study. Phase 1 was an acute course of right unilateral ultrabrief pulse ECT, combined with open-label venlafaxine at seven academic medical centers. In phase 2 (reported separately), patients who had remitted were randomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus continuation ECT. In phase 1, depressed patients received high-dose ECT (at six times the seizure threshold) three times per week. Venlafaxine was started during the first week of treatment and continued throughout the study. The primary outcome measure was remission, assessed with the 24-item Hamilton Depression Rating Scale (HAM-D), which was administered three times per week. Secondary outcome measures were post-ECT reorientation and safety. Paired t tests were used to estimate and evaluate the significance of change from baseline in HAM-D scores. Results: Of 240 patients who entered phase 1 of the study, 172 completed it. Overall, 61.7% (148/240) of all patients met remission criteria, 10.0% (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met response criteria. Among those who remitted, the mean decrease in HAM-D score was 24.7 points (95% CI=23.4, 25.9), with a mean final score of 6.2 (SD-2.5) and an average change from baseline of 79%. The mean number of ECT treatments to remission was 7.3 (SD=3.1). Conclusions: Right unilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and highly effective treatment option for depressed geriatric patients, with excellent safety and tolerability. These data add to the evidence base supporting the efficacy of ECT to treat severe depression in elderly patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available